Target selection and safety assessment: Navigating early decisions that shape drug development

In drug discovery, few moments carry as much weight as the earliest go/no go decisions. This is where teams evaluate whether a biological target is both scientifically compelling and safe enough to justify investment. Target selection and safety assessment may sound straightforward, but the reality is far more complex—and the consequences of misjudgment are significant.

Teams across R&D now recognize that strengthening the safety lens at this early inflection point can reduce costly late-stage failures, improve translational confidence and accelerate the path to viable therapies.

Why early target safety assessment is so challenging

Scientific enthusiasm for a target is rarely enough. The biology itself holds the potential for unintended effects, and those liabilities may not reveal themselves until years into development. This challenge is intensified by three factors:

1. The persistent translation gap

Often referred to as the “valley of death,” the space between preclinical promise and clinical reality remains a major barrier. Many targets look encouraging in model systems, only to falter later due to unexpected toxicities or mechanisms that don’t translate to human biology.

Bridging this gap requires not just better data, but better interpretation—and that starts with understanding the full safety landscape surrounding a target early on.

2. Fragmented and evolving safety evidence

Safety-relevant information is scattered across:

• peer-reviewed studies
• conference abstracts
• regulatory documents
• clinical trial registries
• company communications
• post‑marketing surveillance datasets

Each provides a small window into a target’s risk profile, but independently, none tell the full story. Teams must determine which signals matter, which don’t, and where uncertainty still lies.

3. Increasing target complexity

Therapeutic innovation is pushing into pathways, multimodal mechanisms, and target classes that are less understood and more interconnected. As an example, inflammatory signaling cascades involving kinases such as IRAK family members create layers of upstream and downstream interactions. Safety risks may arise from any point in the network, not just the target directly under investigation.

The business case for earlier and deeper assessment

The strategic opportunity behind stronger target safety assessments is clear: minimizing avoidable risk before it becomes expensive.

Reducing late-stage attrition

Clinical trials remain the most resource-intensive phase of drug development. By identifying potential toxicities or red flag mechanisms early, teams avoid advancing assets that are likely to fail later—saving both time and capital.

Supporting confident Go/No Go decisions

Investing in a target is a commitment measured in years. With better visibility into known adverse events, pathway-level interactions, related target families and precedent from similar mechanisms, teams can move forward with greater conviction — or pivot sooner when warranted.

Understanding competitive and mechanistic context

Knowing how similar targets have performed can:

• highlight previously observed safety issues
• reveal differentiating opportunities
• help anticipate regulators’ expectations
• inform biomarker or patient stratification strategies

This is especially important when dealing with novel targets where little direct evidence exists.

Accelerating internal alignment

Clear, structured safety assessments help cross-functional teams—from discovery scientists to toxicologists to clinical strategists—work from the same playbook. When safety insights are presented coherently, teams spend less time reconciling data and more time making decisions.

What a modern target safety assessment looks like

A contemporary, high-quality target safety assessment integrates diverse evidence into a single view of risk. While the methods and tools vary, the goal is to anticipate issues before they manifest downstream.

1. Mapping safety signals across data types

For any given target, a robust assessment examines:

• preclinical findings, including in vitro and in vivo toxicology
• clinical adverse events associated with drugs modulating the same target
• biological functions and expression profiles
• disease-related roles that may indicate higher risk
• pathway involvement and network effects
• target family relationships that may hint at shared liabilities

The challenge isn’t just collecting this information—it’s interpreting how the pieces interact.

2. Evaluating Target Biology in Context

Pathway-level analysis is particularly important. For example, when evaluating inflammatory signaling targets such as IRAK4 or IRAK2, safety teams benefit from understanding:

• how upstream or downstream nodes behave
• which adverse events have been linked to related genes
• whether modulating a target could compromise immune function or increase infection susceptibility
• whether parallel mechanisms may compensate or amplify risk

Biology rarely operates in isolation. A single target can influence multiple systems, and even subtle modulations may create unintended clinical consequences.

3. Examining mechanistic plausibility

Not every safety signal carries equal weight. Teams must determine:

• whether mechanistic evidence supports the risk
• whether the adverse event has been observed across multiple modalities
• whether the effect could be off target rather than target-driven
• how dose, route, or patient population may influence outcomes

The key is distinguishing between coincidental associations and biologically meaningful patterns.

4. Prioritizing uncertainty

In early development, knowledge gaps matter just as much as known risks. A meaningful assessment calls out:

• missing or sparse evidence
• areas where findings are contradictory
• populations where risk may be higher
• mechanistic hypotheses that require validation

Uncertainty is actionable—when surfaced early.

Moving toward better early decisions

Across R&D organizations, interest in strengthening early target selection and safety assessment is accelerating. Teams want greater clarity, earlier. They want integrated views of biology, mechanism and precedent. And they want to make decisions that reduce downstream risk while preserving agility in fast-moving therapeutic areas.

The opportunity is significant: better assessments mean better-informed pipelines. When teams invest in understanding safety at the target level—not just at the molecule level—they’re better equipped to choose targets that can truly become successful therapies.

Learn more about how OFF-X from Clarivate helps innovators derisk drug development and pharmacovigilance: OFF-X preclinical and clinical safety data | Clarivate

Development Pharma Regulatory Research Safety

content_copy Copy link Copied